Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease.

[1]  C. Hamm,et al.  Baroreceptor stimulation in a patient with preexisting subcutaneous implantable cardioverter defibrillator , 2018, Pacing and clinical electrophysiology : PACE.

[2]  D. Steven,et al.  Combination of a subcutaneous ICD in a patient with a baroreceptor activation device: Feasibility, safety, and precautions: A Case Report , 2017, Pacing and clinical electrophysiology : PACE.

[3]  H. Predel,et al.  [Baroreceptor activation therapy for therapy-resistant hypertension: indications and patient selection : Recommendations of the BAT consensus group 2017]. , 2017, Der Internist.

[4]  M. van der Giet,et al.  Barorezeptorakivierungstherapie bei therapierefraktärer Hypertonie: Indikation und Patientenselektion , 2017, Der Internist.

[5]  G. Bakris,et al.  Sustained Reduction of Blood Pressure With Baroreceptor Activation Therapy: Results of the 6-Year Open Follow-Up , 2017, Hypertension.

[6]  R. Wachter,et al.  Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. , 2016, Seminars in thoracic and cardiovascular surgery.

[7]  D. Perera,et al.  Ischaemic cardiomyopathy: pathophysiology, assessment and the role of revascularisation , 2016, Heart.

[8]  R. Wachter,et al.  Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy , 2015, European journal of heart failure.

[9]  G. Mancia,et al.  Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction , 2015, Journal of hypertension.

[10]  R. Wachter,et al.  Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. , 2015, JACC. Heart failure.

[11]  R. Wachter,et al.  Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. , 2015, JACC. Heart failure.

[12]  G. Mancia,et al.  Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function, and cardiac haemodynamics in heart failure: a proof-of-concept study , 2014, European journal of heart failure.

[13]  Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies. , 2014, World journal of cardiology.

[14]  Yeong-Hoon Choi,et al.  Baroreflex activation therapy in patients with pre-existing implantable cardioverter-defibrillator: compatible, complementary therapies. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[15]  R. Wachter,et al.  Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. , 2012, Journal of the American Society of Hypertension : JASH.

[16]  Karel G M Moons,et al.  Incidence and predictors of short- and long-term complications in pacemaker therapy: the FOLLOWPACE study. , 2012, Heart rhythm.

[17]  E. Irwin,et al.  Chronic Electrical Stimulation of the Carotid Sinus Baroreflex Improves Left Ventricular Function and Promotes Reversal of Ventricular Remodeling in Dogs With Advanced Heart Failure , 2011, Circulation. Heart failure.

[18]  David L Hayes,et al.  Sustained Reverse Left Ventricular Structural Remodeling With Cardiac Resynchronization at One Year Is a Function of Etiology: Quantitative Doppler Echocardiographic Evidence From the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) , 2006, Circulation.

[19]  C. O'connor,et al.  A standardized definition of ischemic cardiomyopathy for use in clinical research. , 2002, Journal of the American College of Cardiology.

[20]  G. Jennings,et al.  Effect of cardiac sympathetic nervous activity on mode of death in congestive heart failure. , 2001, European heart journal.

[21]  F. Follath,et al.  Etiology and response to drug treatment in heart failure. , 1998, Journal of the American College of Cardiology.

[22]  Decreased baroreflex sensitivity in patients with stable coronary artery disease is correlated with the severity of coronary narrowing. , 1996, The American journal of cardiology.

[23]  M. Creager.  Baroreceptor reflex function in congestive heart failure. , 1992, The American journal of cardiology.